Abstract
Metastatic melanoma is one of the most intractable tumors, with all current regimens showing limited survival impact. Failure of most agents is attributed to development of therapy resistance. Accumulated evidence points to the apoptotic defect of melanoma cells and the surge of survival signals stimulated by cytotoxic drugs, as a way that tumors circumvent cytotoxic chemotherapy. An overview of inhibitors developed against these growth/survival factors, which are potential partners to be combined with systemic chemotherapy, will be discussed. The escape mechanism from molecular inhibitors also suggests a “vertical” or “horizontal” combination of molecularly targeted therapies. A better understanding of the interactions between simultaneously used regimens and of the rationale for combination therapy will provide new insights to improve survival and quality of life in patients with advanced melanoma.
Keywords: Melanoma, chemotherapy, drug resistance, targeted therapy, radiation, immunotherapy, dacarbazine, dartmouth regimen, biologics, tremelimumab, ipilimumab, BRAF inhibitor PLX4032, tumor cells, cancer therapy, chemotherapeutic agents
Current Molecular Medicine
Title: Resistance to Chemotherapy and Molecularly Targeted Therapies: Rationale for Combination Therapy in Malignant Melanoma
Volume: 11 Issue: 7
Author(s): S. Wu and R.K. Singh
Affiliation:
Keywords: Melanoma, chemotherapy, drug resistance, targeted therapy, radiation, immunotherapy, dacarbazine, dartmouth regimen, biologics, tremelimumab, ipilimumab, BRAF inhibitor PLX4032, tumor cells, cancer therapy, chemotherapeutic agents
Abstract: Metastatic melanoma is one of the most intractable tumors, with all current regimens showing limited survival impact. Failure of most agents is attributed to development of therapy resistance. Accumulated evidence points to the apoptotic defect of melanoma cells and the surge of survival signals stimulated by cytotoxic drugs, as a way that tumors circumvent cytotoxic chemotherapy. An overview of inhibitors developed against these growth/survival factors, which are potential partners to be combined with systemic chemotherapy, will be discussed. The escape mechanism from molecular inhibitors also suggests a “vertical” or “horizontal” combination of molecularly targeted therapies. A better understanding of the interactions between simultaneously used regimens and of the rationale for combination therapy will provide new insights to improve survival and quality of life in patients with advanced melanoma.
Export Options
About this article
Cite this article as:
Wu S. and Singh R.K., Resistance to Chemotherapy and Molecularly Targeted Therapies: Rationale for Combination Therapy in Malignant Melanoma, Current Molecular Medicine 2011; 11 (7) . https://dx.doi.org/10.2174/156652411800615153
DOI https://dx.doi.org/10.2174/156652411800615153 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibiting HSP90 to Treat Cancer: A Strategy in Evolution
Current Molecular Medicine Proteases as Anti-Cancer Targets - Molecular and Biological Basis for Development of Inhibitor-Like Drugs Against Cancer
Anti-Cancer Agents in Medicinal Chemistry Gene Therapy for Brain Cancer: Combination Therapies Provide Enhanced Efficacy and Safety
Current Gene Therapy Review on Documented Medicinal Plants used for the Treatment of Cancer
Current Traditional Medicine Use of Analogs of Peptide Hormones Conjugated to Cytotoxic Radicals for Chemotherapy Targeted to Receptors on Tumors
Current Drug Delivery Recent Patents, Regulatory Issues, and Toxicity of Nanoparticles in Neuronal Disorders
Current Drug Metabolism Targeting Established Tumor Vasculature: A Novel Approach to Cancer Treatment
Current Cancer Therapy Reviews Majra Honey Abrogated the Normal and Cancer Cells Proliferation Inhibition by Juniperus procera Extract and Extract/Honey Generated AgNPs
Anti-Cancer Agents in Medicinal Chemistry Recent Advance in Isoform-Specific Regulation of Adenylyl Cyclase
Current Enzyme Inhibition Biochemical Strategies to Anticoagulation: A Comparative Overview
Current Vascular Pharmacology Effect of Substituted Benzimidazoles and Somatostatin Analogs on the Vitality of Tumor Cell Lines and on the Oxidative Burst of Phagocytes
Letters in Drug Design & Discovery Beneficiary and Adverse Effects of Phytoestrogens: A Potential Constituent of Plant-based Diet
Current Pharmaceutical Design Reducible Disulfide-Based Non-Viral Gene Delivery Systems
Mini-Reviews in Medicinal Chemistry Expression and Function of PPARs in Cancer Stem Cells
Current Stem Cell Research & Therapy Mechanism of Oxidative Broncho-Epithelial Cell Damage with Reference to Gas Phase Cigarette Smoke
Mini-Reviews in Organic Chemistry Formulations, Pharmacodynamic and Clinical Studies of Nanoparticles for Lung Cancer Therapy - An Overview
Current Drug Metabolism Luminescent Silica Nanoparticles for Cancer Diagnosis
Current Medicinal Chemistry Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics
Current Medicinal Chemistry Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy
Current Cancer Drug Targets Patent Selections
Recent Patents on Food, Nutrition & Agriculture